# Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

> **NCT00322673** · PHASE2 · TERMINATED · sponsor: **Symphony Evolution, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- AML

## Interventions

- **DRUG:** XL999

## Key facts

- **NCT ID:** NCT00322673
- **Lead sponsor:** Symphony Evolution, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2006-11
- **Final completion:** 2007-05
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Study was terminated due to cardiac toxicities
- **Last updated:** 2010-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322673, "Study of XL999 in Patients With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00322673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*